Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: A randomized, double-blind, parallel-controlled, multi-centre trial

International Journal of Neuropsychopharmacology

Volumn 16, Issue 7, 2013, Pages 1529-1537

  Zhang, Lina ^a   Zhang, Zhiqin ^a   Chen, Yangmei ^a   Qin, Xinyue ^b   Zhou, Huadong ^c   Zhang, Chaodong ^d   Sun, Hongbin ^e   Tang, Ronghua ^f   Zheng, Jinou ^g   Yi, Lin ^h   Deng, Liying ⁱ   Li, Jinfang ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d First Affiliated Hospital of China Medical University   (China)

^e SICHUAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^h DALIAN MEDICAL UNIVERSITY   (China)

ⁱ NANCHANG UNIVERSITY   (China)

Author keywords

Key words Efficacy; monoamine oxidase inhibitors; Parkinson's disease; rasagiline; safety

Indexed keywords

AMANTADINE; BENSERAZIDE PLUS LEVODOPA; BROMOCRIPTINE; MADAPAR; PIRIBEDIL; PLACEBO; PRAMIPEXOLE; RASAGILINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; BRADYKINESIA; CHINESE; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; PAIN; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RIGIDITY; SIDE EFFECT; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; XEROSTOMIA;

ADULT; AGED; ANTIPARKINSON AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; COGNITION DISORDERS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDANS; LEVODOPA; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84880518583     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145713000175     Document Type: Article

References (25)

1. Abu-Raya S, Blaugrund E, Trembovler V, Shilderman-Bloch E, Shohami E, Lazarovici P (1999) Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res 58:456-463.
2. Ahlskog JE (1999) Medical treatment of later-stage motor problems of Parkinson's disease. Mayo Clin Proc 74: 1239-1254.
3. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R) salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82:913-923.
4. Benito-Leó J, Bermejo-Pareja F, Rodríguez J, Molina JA, Gabriel R, Morales JM, Neurological Disorders in Central Spain (NEDICES) Study Group (2003) Prevalence of PD and other types of Parkinsonism in three elderly populations of central Spain. Mov Disord 18:267-274.
5. Hamani C, Lozano AM (2003) Physiology and pathophysiology of Parkinson's disease. Ann N Y Acad Sci 991:15-21.
6. Lecht S, Haroutiunian S, Hoffman A, Lazarovici P (2007) Rasagiline-a novel MAO B inhibitor in Parkinson's disease therapy. Ther Clin Risk Manag 3:467-474.
7. Malaty IA, Fernandez HH (2009) Role of rasagiline in treating Parkinson's disease: effect on disease progression. Ther Clin Risk Manag 5:413-419.
8. Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M (2000) Mechanism underlying antiapoptotic activity of a deprenyl-related propargylamine, rasagiline. Mech Ageing Dev 116:181-191.
9. Olanow CW (2006) Rationale for considering that propargylamines might be neuroprotective in Parkinson's disease. Neurology 66:S69-S79.
10. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, Rascol O (2008) A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics. Mov Disord 23:2194-2201.
11. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): Treatment guidelines. Neurology 56:S1-S88.
12. Parkinson Study Group (2002) A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 59:1937-1943.
13. Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561-566.
14. Parkinson Study Group (2005) A randomized placebocontrolled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study. Arch Neurol 62:241-248.
15. Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group (2000) Rasagiline mesylate, a new MAOB inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to Levodopa. Clin Neuropharmacol 23:324-330.
16. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial. Lancet 365:947-954.
17. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C (2002) Treatment interventions for Parkinson's disease: An evidence based assessment. Lancet 359:1589-1598.
18. Robottom BJ (2011) Efficacy, safety, and patient preference of monoamine oxidase B inhibitors in the treatment of Parkinson's disease. Patient Prefer Adherence 5:57-64.
19. Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25:35-44.
20. Speiser Z, Levy R, Cohen S (1998) Effects of N-propargyl-1-(R) aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 52:287-300.
21. Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, Finberg J (1998) R(+) N-propargyl-1- aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine-oxidase B. J Neural Transm Suppl 52:301-305.
22. Stern MB, Marek KL, Friedman J, Hauser RA, LeWitt PA, Tarsy D, Olanow CW (2004) Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 19:916-923.
23. Youdim MB (1995) The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction. Acta Psychiatr Scand Suppl. 386:5-7.
24. Youdim MB, Wadia A, Tatton W, Weinstock M (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450-458.
25. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, Le W (2008) Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neurochem 105:1970-1978.